You are here

Novartis

With FDA decision near, Novartis bolsters SMA gene therapy case

With FDA decision near, Novartis bolsters SMA gene therapy case

Biopharma Dive

spinal muscular atrophy

Flag link:

FDA accepts BLA for Novartis' AMD therapy

FDA accepts BLA for Novartis' AMD therapy

BioCentury

wet age-related macular degeneration

Flag link:

Manufacturing problems persist for Aurobindo, U.S.' second-largest generics producer

Manufacturing problems persist for Aurobindo, U.S.' second-largest generics producer

Fierce Pharma

drug manufacturing

Flag link:

Novartis bribery investigation craters after Greek prosecutors clear 4 officials

Novartis bribery investigation craters after Greek prosecutors clear 4 officials

Fierce Pharma

Flag link:

It’s a seller’s world in biotech M&A, and Novartis CEO Vas Narasimhan has his check book out and pen ready

It’s a seller’s world in biotech M&A, and Novartis CEO Vas Narasimhan has his check book out and pen ready

Endpoints

Flag link:

Novartis completes spin-out of Alcon eye unit

Novartis completes spin-out of Alcon eye unit

Pharmaforum

Flag link:

Scotland backs Aimovig for migraine after NICE says no

Scotland backs Aimovig for migraine after NICE says no

Pharmaforum

Flag link:

The top 15 pharma companies by 2018 revenue

The top 15 pharma companies by 2018 revenue

Fierce Pharma

Bristol-Myers Squibb

Gilead Sciences

Teva Pharmaceutical

Flag link:

Lawsuit over migraine deal could be good for Amgen, analysts say

Lawsuit over migraine deal could be good for Amgen, analysts say

Marketwatch

Flag link:

Amgen and Novartis file dueling lawsuits over their deal to market a migraine drug

Amgen and Novartis file dueling lawsuits over their deal to market a migraine drug

Stat

Flag link:

Novartis sues Amgen over migraine treatment Aimovig

Novartis sues Amgen over migraine treatment Aimovig

Yahoo/Reuters

Flag link:

Novartis CEO's $50 Billion of Deals Was Just the First Act

Novartis CEO's $50 Billion of Deals Was Just the First Act

Yahoo/Bloomberg

Flag link:

Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER

Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER

Fierce Pharma

spinal muscular atrophy

Flag link:

Sandoz resubmission puts Amgen's Neulasta at further risk of competition

Sandoz resubmission puts Amgen's Neulasta at further risk of competition

Biopharma Dive

Flag link:

Another day, another $100M-plus biotech megaround as radiopharmaceuticals’ popularity grows

Another day, another $100M-plus biotech megaround as radiopharmaceuticals’ popularity grows

Endpoints

Fusion Pharmaceuticals

radiopharmaceuticals

Flag link:

Novartis' AveXis buys AstraZeneca site in Colorado as it anticipates gene therapy launch

Novartis' AveXis buys AstraZeneca site in Colorado as it anticipates gene therapy launch

Fierce Pharma

drug manufacturing

Flag link:

Did Novartis hand out kickbacks or host educational dinners? A jury may decide

Did Novartis hand out kickbacks or host educational dinners? A jury may decide

Fierce Pharma

physician payments

Flag link:

Novartis Adds Inflammation Drugs to Pipeline with Deal for IFM Tre

Novartis Adds Inflammation Drugs to Pipeline with Deal for IFM Tre

Xconomy

anti-inflammatory

Flag link:

2 Blockbuster Gene Therapy Programs to Watch in 2019

2 Blockbuster Gene Therapy Programs to Watch in 2019

Motley Fool

Flag link:

3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop

3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop

Motley Fool

Alzheimer's disease

Axsome Therapeutics

Flag link:

Pages